Pediatrix Medical Group (NYSE:MD) Price Target Cut to $15.00 by Analysts at Truist Financial

Pediatrix Medical Group (NYSE:MD) had its target price cut by Truist Financial from $16.00 to $15.00 in a research report released on Monday morning,Benzinga reports. They currently have a hold rating on the stock.

MD has been the subject of several other research reports. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, December 19th. Mizuho raised their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Jefferies Financial Group upped their price objective on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Finally, Macquarie assumed coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 target price on the stock. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $16.25.

Pediatrix Medical Group Stock Up 1.0 %

Shares of NYSE MD opened at $12.73 on Monday. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -4.16, a PEG ratio of 2.00 and a beta of 1.58. The company has a quick ratio of 1.42, a current ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm’s fifty day moving average is $14.34 and its 200 day moving average is $11.53. Pediatrix Medical Group has a 52 week low of $6.62 and a 52 week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The firm had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.29 earnings per share. On average, equities research analysts expect that Pediatrix Medical Group will post 1.26 earnings per share for the current year.

Insider Activity

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the transaction, the executive vice president now directly owns 135,810 shares in the company, valued at $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the sale, the director now directly owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Quest Partners LLC lifted its stake in shares of Pediatrix Medical Group by 25.6% during the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after buying an additional 622 shares in the last quarter. Everence Capital Management Inc. raised its holdings in Pediatrix Medical Group by 7.5% during the fourth quarter. Everence Capital Management Inc. now owns 13,840 shares of the company’s stock valued at $182,000 after acquiring an additional 960 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Pediatrix Medical Group by 3.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,387 shares of the company’s stock valued at $245,000 after acquiring an additional 1,088 shares in the last quarter. Quarry LP boosted its stake in shares of Pediatrix Medical Group by 54.1% in the third quarter. Quarry LP now owns 4,735 shares of the company’s stock worth $55,000 after acquiring an additional 1,662 shares during the period. Finally, Bank of Montreal Can grew its position in shares of Pediatrix Medical Group by 0.5% during the second quarter. Bank of Montreal Can now owns 415,110 shares of the company’s stock worth $3,196,000 after purchasing an additional 2,083 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.